Notícias Adlai Nortye Ltd - ANL | Ações NASDAQ | ADVFN Brasil

Índice Bovespa

US Dollar vs BRL

As Melhores Corretoras Online

Negocie de forma mais inteligente, não mais difícil: Libere seu potencial com nosso conjunto de ferramentas e discussões ao vivo.

Cadastre-se

Início
Investir
Ações
EUA
NASDAQ
Adlai Nortye Ltd (ANL)
Adlai Nortye Ltd (ANL) Notícias

Adlai Nortye Ltd (ANL)

2,2062

-0,0138

( -0,62% )

Atualizado: 12:21:39

Atrasado por 15 minutos

Capacite seu portfólio: Discussões em tempo real e ideias de negociação acionáveis.

Adlai Nortye Reports Unaudited First Half 2024 Financial Results and Highlights Recent Operational Progress

Adlai Nortye Appoints Roger Sawhney, M.D. to Its Board of Directors

Adlai Nortye Ltd. to Present Encouraging Data of the Combination of AN0025 and Definitive Chemoradiotherapy (dCRT) at ASCO 2024

Adlai Nortye Announces First Patient Dosed in Randomized Phase II Clinical Trial of Palupiprant (AN0025) for the Treatment of Locally Advanced Rectal Cancer with Radiation Therapy

Form S-8 - Securities to be offered to employees in employee benefit plans

Adlai Nortye Announces Appointment of Dr. Archie Tse as the Head of Research & Development

Adlai Nortye Announces Completion of Patient Enrollment in Global Phase III Clinical Trial of Buparlisib (AN2025) in Combination with Paclitaxel for the Treatment of Recurrent or Metastatic HNSCC

Adlai Nortye Ltd. & Nucleai awarded ESMO 2023 BEST Poster Award

Adlai Nortye Ltd. Announces Closing of Initial Public Offering

Adlai Nortye Ltd. Announces Pricing of Initial Public Offering

Further re Dir Change

FRN Variable Rate Fix

Completion of Italy sale

FRN Variable Rate Fix

Director Shareholding

Fóruns

Nenhuma Discussão Encontrada

Criar Nova Discussão

Delayed Upgrade Clock

Suporte: (11) 4950 5808 | suporte@advfn.com.br

Ao acessar os serviços da ADVFN você estará de acordo com os Termos e Condições